II. β-Blockers and cardiac protection: 5 yr on from POISE
نویسندگان
چکیده
منابع مشابه
Hemangiomas and β-Blockers: On the Rebound.
Infantile hemangioma (IH) is the most common tumor of childhood, and although most lesions eventually involute, the proliferative phase may be associated with complications, such as ulceration, bleeding, functional compromise, and anatomic disfigurement. Rarely, IH can have major or life-threatening consequences, such as airway obstruction, high-output congestive heart failure, and consumptive ...
متن کاملBeta-Blockers for non-cardiac surgery: a different approach after the poise data or await more information?
Bruce M. Biccard1,2,3 1Honorary Lecturer, Nelson R Mandela School of Medicine, Private Bag 7, Congella, 4013, South Africa. 2Honorary Senior Clinical Lecturer, Nuffield Department of Anaesthetics, University of Oxford, John Radcliffe Hospital, Headley Way, Headington, Oxford, OX3 9DU, United Kingdom. 3Principal Specialist, Inkosi Albert Luthuli Central Hospital, 800 Bellair Road, Mayville, 4091...
متن کاملβ-Alanine and orotate as supplements for cardiac protection
Correspondence to Dr James J DiNicolantonio; [email protected] CARNOSINE: ACID BUFFER, ANTIOXIDANT AND AID TO MUSCLE CONTRACTION β-Alanine is a rate-limiting precursor for synthesis of the dipeptide carnosine (β-alanyl-L-histidine), which is produced within and stored in high concentrations in skeletal muscle, heart and olfactory receptor neurons. 2 β-Alanine supplementation has been shown to...
متن کاملCardiovascular Protection Using Beta-Blockers
For more than 3 decades, beta-blockers have been widely used in the treatment of hypertension and are still recommended as first-line agents by national and international guidelines. Recent meta-analyses indicate that, in patients with uncomplicated hypertension, compared with other antihypertensive agents, first-line therapy with beta-blockers was associated with an increased risk of stroke, e...
متن کاملβ-blockers for COPD inpatients.
For clinicians who treat patients with respiratory diseases, the use of β-blockers has, for a long time, posed a dilemma because of the potential risk of bronchospasm and neutralisation of the effectiveness of β-2 agonists. This predicament is particularly challenging for patients with chronic obstructive pulmonary disease (COPD), many of whom have substantial cardiovascular comorbidity, and in...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Anaesthesia
سال: 2014
ISSN: 0007-0912
DOI: 10.1093/bja/aet437